Workshops

ANR2018 WORKSHOPS

Please find information below on the invited Workshops that have been confirmed to-date for ANR2018. This information will be updated as the conference nears.

Immunotherapy Beyond GD2 for the Oncologist: Role of T cells, NK cells, PD1 and the Microenvironment


Wednesday May 9, 2018, 1:00-3:00 PM

Co-Chairs:
Ira Mellman, PhD (Genentech, Inc.)
Crystal Mackall, MD (Stanford University, Stanford CA)

Speakers:
John Maris, MD (Children’s Hospital of Philadelphia)
Nai-Kong Cheung, MD, PhD (Memorial Sloan Kettering Cancer Center, NY)
Ira Mellman, PhD (Genentech Inc.)
Crystal Mackall, MD (Stanford University, Stanford CA)

The immunotherapy workshop may include optimal preclinical models for immunotherapy, targeting the microenvironment, combination immunotherapies, cellular therapies with NK cells, CAR-T cells, vaccines, ongoing clinical trials, and toxicities.

 

New Biomarker Technologies: Descriptive, Prognostic, Predictive?


Wednesday May 9, 2018, 3:30-5:30 PM

Co-Chairs:
Gudrun Schleiermacher, MD, PhD (Curie Institute, France)
Allison Welsh, PhD (Foundation Medicine, Cambridge MA)

Speakers:
Gudrun Schleiermacher, MD, PhD (Curie Institute, France)
Michael Angelo, MD, PhD (Stanford University, Stanford CA)
Allison Welsh, PhD (Foundation Medicine, Cambridge MA)
Katleen de Preter, MD (Ghent University, Ghent, Belgium)

This workshop will provide a presentation and discussion of cutting-edge translational biomarker technologies for the study of Neuroblastoma. In the first half, an overview of new technologies for assessing tissue and circulating biomarkers will be presented, beginning with next-generation imaging technologies such as multiplexed ion beam imaging (MIBI) and cytometry by time of flight (CytOF). Technical approaches for liquid biopsies will also be discussed, highlighting different methodologies for the study of circulating tumor DNA (ctDNA), miRNA, CTCs, and other circulating molecules. In the second half, we will narrow our focus to ctDNA biomarkers, and discuss the challenges and opportunities for developing and validating ctDNA assays for clinical use. This will include a group discussion, focusing on opportunities for collaboration and pooling of data, as well as how we should be thinking about clinical utility and the possibility of integrating ctDNA into clinical practice

 

RNA and PostTranslational Control: How Do We Identify Protein Drivers as Targets


Thursday, May 10, 2018, 1:00-3:00 PM

Co-Chairs:
Poul Sorensen, MD, PhD (University of British Columbia, Vancouver)
William Weiss, MD, PhD (University of California, San Francisco)

Speakers:
Davide Ruggero, PhD (University of California, San Francisco)
Anne Willis, PhD (MRC Toxicology Unit, United Kingdom)
Poul Sorensen, MD, PhD (University of British Columbia, Vancouver)
Nahum Sonenberg, PhD (McGill University, Montreal) 

This workshop will explore the roles of altered mRNA translational regulation in cancer development, including how translation control influences adaptive responses to oncogenic stress, as well as pharmacological approaches to target the translation machinery in neuroblastoma.

 

Precision Medicine: Optimal Trial Design, Predictive Biomarkers, Efficacy 


Thursday May 10, 2018, 3:30-5:30 PM

Co-Chairs:
Brian Alexander, MD, MPH (Dana-Farber/Harvard Cancer Center)
Yael Mosse, MD (Children’s Hospital of Philadelphia)

Speakers:
Donald Berry, PhD (The University of Texas MD Anderson Cancer Center)
Gilles Vassal, PhD (Institut Gustave-Roussy, France)
Brian Alexander, MD, MPH (Dana-Farber/Harvard Cancer Center)
Yael Mosse, MD (Children’s Hospital of Philadelphia)

This workshop will examine and discuss challenges and best practices for effectively utilizing genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials in neuroblastoma and across a variety of pediatric cancers.

 

Want to Learn More About Registration?

Click here